Stockscreener 앱 받기
36.18
1.83%
0.65
시간 외 거래:
36.59
0.41
+1.13%
전일 마감가:
$35.53
열려 있는:
$36.1
하루 거래량:
884.65K
Relative Volume:
1.26
시가총액:
$15.36B
수익:
$5.81B
순이익/손실:
$412.00M
주가수익비율:
38.49
EPS:
0.94
순현금흐름:
-
1주 성능:
+4.30%
1개월 성능:
+13.42%
6개월 성능:
-1.63%
1년 성능:
+40.72%
1일 변동 폭
$35.66
$36.25
1주일 범위
$34.52
$36.25
52주 변동 폭
$23.91
$38.79
Smith Nephew Plc Adr Stock (SNN) Company Profile
Compare SNN vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
36.18 | 15.08B | 5.81B | 412.00M | 0 | 0.94 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-14 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-04-25 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-03-12 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-06 | 다운그레이드 | Berenberg | Buy → Hold |
| 2024-11-01 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-07-24 | 개시 | Deutsche Bank | Buy |
| 2024-06-05 | 업그레이드 | UBS | Neutral → Buy |
| 2023-11-28 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2023-11-03 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-10-31 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2023-10-13 | 개시 | Stifel | Hold |
| 2023-08-08 | 업그레이드 | UBS | Sell → Neutral |
| 2023-04-27 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-12 | 개시 | Citigroup | Buy |
| 2022-11-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-07-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-03-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-15 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-04 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-06-09 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-18 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-12-01 | 개시 | Barclays | Overweight |
| 2020-07-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-04 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-11-21 | 개시 | Citigroup | Buy |
| 2019-11-12 | 개시 | Bernstein | Outperform |
| 2019-07-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2019-02-08 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2019-01-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-11-01 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-25 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-10-11 | 개시 | Canaccord Genuity | Buy |
| 2017-02-27 | 다운그레이드 | Goldman | Buy → Neutral |
| 2017-01-19 | 개시 | HSBC Securities | Hold |
| 2016-12-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2016-10-06 | 다운그레이드 | Berenberg | Buy → Hold |
| 2016-02-26 | 개시 | Cantor Fitzgerald | Hold |
모두보기
Smith Nephew Plc Adr 주식(SNN)의 최신 뉴스
Anti-Biofilm Agents Market to Worth Over USD 4.32 Billion By 2035 | Escalating Hospital Infection Rates Drive Urgent Clinical Agent Adoption and Market Growth says Astute Analytica - GlobeNewswire Inc.
Jim Cramer on Smith & Nephew: "This Group, I Do Not Like" - Finviz
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair - Finviz
The Truth About Smith & Nephew plc: Why This ‘Boring’ Med-Tech Stock Might Be Your Sneaky Power - AD HOC NEWS
Smith & Nephew ADR trying to close in on key technical benchmark - MSN
The Truth About Smith & Nephew plc (ADR): Wall Street Sleeper Stock or Total Snooze? - AD HOC NEWS
Smith & Nephew plc (ADR): Quiet Charts, Cautious Optimism – Is SNN a Sleeper in Medtech? - AD HOC NEWS
Smith & Nephew (SN, SNN) Stock Outlook for December 2025: Q3 Setback, $500m Buyback and What Comes Next - ts2.tech
Smith and Nephew (LON:SN) positioned across FTSE 100 Today healthcare landscape - Kalkine Media
FTSE 100 today: Pound lower; Magnum debuts, Smith & Nephew sets new goals - Investing.com
Smith & Nephew Unveils RISE Blueprint for a Stronger Future - Kalkine Media
Smith+Nephew sets ambitious growth targets through 2028 - Investing.com
Smith & Nephew (SNN) Stock Forecast 2026: Q3 2025 Results, $500m Buyback and New Board Signals - TechStock²
Smith & Nephew PLC (NYSE:SNN): A Value Investment in Medical Devices - Chartmill
[6-K] SMITH & NEPHEW PLC Current Report (Foreign Issuer) | SNN SEC FilingForm 6-K - Stock Titan
Smith & Nephew PlcDirector/PDMR Shareholding - Research Tree
REGSmith & Nephew PlcDirector/PDMR Shareholding - TradingView
Smith & Nephew stock initiated with Buy rating at Kepler Cheuvreux - Investing.com
Shell Stock Price Today (12 Nov 2025): SHEL ADR edges lower as oil slides; London closes at 2,909p amid fresh buyback and Volta Media sale - ts2.tech
Smith+Nephew shares tumble as Q3 sales miss expectations - Investing.com
Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Price Target at $36.75 - Defense World
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT - Sahm
Predictions - sharewise.com
UFC® and Smith+Nephew announce multi-year extension of partnership - The Globe and Mail
Smith & Nephew stock price target raised to GBP17 by RBC on growth outlook - Investing.com Australia
Smith & Nephew schedules third quarter trading report release for November 6 - Investing.com
BlackRock Adjusts Voting Rights in Smith & Nephew - The Globe and Mail
Smith & Nephew stock rating downgraded by Bernstein as valuation recovers - Investing.com
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant - Sahm
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention - Sahm
Smith & Nephew’s ratings affirmed by Moody’s with positive outlook - Investing.com
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty - The Globe and Mail
Park Avenue Securities LLC Acquires 583 Shares of Smith & Nephew SNATS, Inc. $SNN - Defense World
Smith & Nephew CFO John Rogers relocates to US, receives revised compensation - Investing.com
Citi Keeps Their Hold Rating on Koninklijke Philips N.V. (0LNG) - The Globe and Mail
Smith Nephew Plc Adr (SNN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.33%
0.51%
자본화:
|
볼륨(24시간):